ANIK Anika Therapeutics, Inc.

8-K Current Report

Filed: February 26, 2026

Health Care

Surgical & Medical Instruments & Apparatus

Anika Therapeutics, Inc. (ANIK) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure/Election of Directors or Officers

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q1 2025 earnings press release issued; full results in Exhibit 99.1
• Filing structured as Reg FD-compliant disclosure; not subject to Section 18 liability

Item 5.02 · Departure/Election of Directors or Officers

• EVP, General Counsel & Corporate Secretary Colleran departing May 1, 2026 — key legal leadership exit with succession risk
• Through May 1, Colleran retains current salary/benefits and equity continues vesting, but no vacation accrual

+2 more insights

Get deeper insights on Anika Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.